Short communication
Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 °C whole body hyperthermia in patients with refractory sarcoma

https://doi.org/10.1016/0959-8049(95)00622-2Get rights and content

Abstract

Two earlier studies resulted in the design of a phase II trial of 41.8 °C (x 60 min) extracorporeal whole body hyperthermia (WBH) with ICE, i.e. ifosfamide (5 g/m2), carboplatin (300 mg/m2) and etoposide given with WBH, as well as, day 2 and 3 post-WBH (100 mg/m2) for adult patients with refractory sarcoma. 12 patients entered this trial; all were evaluable. 8 patients had a history of prior chemotherapy associated with disease progression. Following WBH/ICE, 7 partial remissions were observed (58%); 3 patients experienced disease stabilisation; the aforementioned 10 patients each received four cycles of therapy. 2 patients exhibited progressive disease. Episodes of WHO graded (grade 3; grade 4) toxicity observed included: anaemia (2;2); leucopenia (5;7); thrombocytopenia (1;6); renal (0;1). Other toxicities (grade 1 and 2) included: anasarca, diarrhoea, ventricular arrhythmias, pressure sores and perioral herpes simplex.

References (15)

  • HI Robins et al.

    Cytokine induction by 41.8 °C whole body hyperthermia

    Cancer Lett

    (1995)
  • HI Robins et al.

    A new technological approach to radiant heat whole body hyperthermia

    Cancer Lett

    (1994)
  • GJ Wiedemann et al.

    Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedichloroplatinum (II) cytotoxicity on humanderived breast carcinoma and sarcoma xenografts in nude mice

    J Cancer Res Clin Oncol

    (1992)
  • GJ Weidemann et al.

    Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide

    Cancer Res

    (1993)
  • JD Cohen et al.

    Thermal enhancement of tetraplatin and carboplatin in human leukemia cells in vitro

    Int J Hyperhermia

    (1990)
  • E Tapazoglou et al.

    Whole body hyperthermia and carboplatin: cytotoxicity for murine leukemia and normal marrow

    Br J Cancer

    (1991)
  • D Ohno et al.

    Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats

    Cancer Res

    (1991)
There are more references available in the full text version of this article.

Cited by (61)

  • An insight into the agents used for immunomodulation and their mechanism of action

    2023, How Synthetic Drugs Work: Insights into Molecular Pharmacology of Classic and New Pharmaceuticals
  • Whole-body hyperthermia in combination with systemic therapy in advanced solid malignancies

    2019, Critical Reviews in Oncology/Hematology
    Citation Excerpt :

    The remaining 14 studies combined WBH with systemic therapy in patients with a specific malignancy (phase II). For ovarian cancer (n = 3 (Atmaca et al., 2009; Douwes et al., 2004; Westermann et al., 2001)), colorectal cancer (n = 2 (Hegewisch-Becker et al., 2002; Hildebrandt et al., 2004)), lung cancer (n = 2 (Engelhardt et al., 1982; Neumann et al., 1982)) and sarcoma (n = 3 (Bull et al., 1992; Westermann et al., 2003; Wiedemann et al., 1996)) more than one trial has been performed. Single studies are available for cervical cancer (Richel et al., 2004), pancreatic cancer (Bakshandeh-Bath et al., 2009), melanoma (Engelhardt et al., 1990) and pleural mesothelioma (Bakhshandeh et al., 2003) (Table 2).

View all citing articles on Scopus
View full text